Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD
Papers referenced int the video:
Joint distribution of lipoprotein cholesterol classes. The Framingham study.
https://pubmed.ncbi.nlm.nih.gov/6573877/
Continue reading “How Many Calories Are Optimal For Health?” »
This paper suggests that ATP release induced by the SARS-CoV-2 virus plays a key role in the genesis of the major symptoms and complications of COVID-19. Infection of specific cells which contain the Angiotensin-Converting Enzyme 2 (ACE2) receptor results in a loss of protection of the Mineralocorticoid Receptor (MR). Local activation by cortisol stimulates the release of ATP initially into the basolateral compartment and then by lysosomal exocytosis from the cell surface. This then acts on adjacent cells. In the nose ATP acts as a nociceptive stimulus which results in anosmia. It is suggested that a similar paracrine mechanism is responsible for the loss of taste. In the lung ATP release from type 2 alveolar cells produces the non-productive cough by acting on purinergic receptors on adjacent neuroepithelial cells and activating, via the vagus, the cough reflex. Infection of endothelial cells results in the exocytosis of WeibelPalade bodies. These contain the Von Willebrand Factor responsible for micro-clotting and angiopoietin-2 which increases vascular permeability and plays a key role in the Acute Respiratory Distress Syndrome. To test this hypothesis this paper reports proof of concept studies in which MR blockade using spironolactone and low dose dexamethasone (SpiDex) was given to PCR-confirmed COVID-19 patients. In 80 patients with moderate to severe respiratory failure 40 were given SpiDex and 40 conventional treatment with high dose dexamethasone (HiDex). There was 1 death in the HiDex group and none in the SpiDex. As judged by clinical, biochemical and radiological parameters there were clear statistically significant benefits of SpiDex in comparison to HiDex. A further 20 outpatients with COVID-19 were given SpiDex. There was no control group and the aim was to demonstrate safety. No adverse effects were noted and no patient became hyperkalaemic. 90% were asymptomatic at 10 days. The very positive results suggest that blockade of the MR can produce major benefit in COVID19 patients. Further larger controlled studies of inpatients and outpatients are required not only for SARS-CoV-2 infection per se but also to determine if this treatment affects the incidence of Long COVID.
Early in the course of the SARS-CoV-2 pandemic it became clear that one of the commonest symptoms was loss of smell and/or taste. Self-reported alterations in smell and taste were detailed in a meta-analysis of 3,563 confirmed cases of COVID-19. They found that the overall prevalence of smell or taste impairment was 47% rising to 67% in patients with more severe disease. In about 20% of patients it was an isolated presenting symptom. Han et al. reviewed the pathophysiology of anosmia in upper respiratory tract infections. Many rhinovirus infections of the nasal olfactory epithelium produce post-viral anosmia which persists for weeks or months until the cell damage is repaired. Post-viral anosmia has been reported with HCoV-229E infection with the olfactory dysfunction lasting more than 6 months. This corona virus does not use ACE2 to get into cells. Conductive or obstructive anosmia is often found with the common cold virus.
Paradromics is a company developing brain computer interfaces that will help people with disabilities in communicating again. Their product will be the brain computer interface with the highest data rate ever developed. Will it compete with other companies like Neuralink or Kernel in the race to reading the brain?
0:00 Introduction to Paradromics.
1:45 The Product.
5:57 The Surgery.
7:41 Commercial availability.
Continue reading “A competitor of Elon Musk and NEURALINK? Let’s take a look at PARADROMICS” »
Boyden’s award-winning research has led to tools that can activate or silence neurons with light, enabling the causal assessment of how specific neurons contribute to normal and pathological brain functions.
Continue reading “Ed Boyden on Optogenetics —- selective brain stimulation with light” »
This could be the key to preventing or stopping cancer metastasis which is the primary cause of death due to cancer.
99% of breast cancer patients survive five years after diagnosis, only 29% do if the cancer has metastasized, according to current numbers from the National Cancer Institute.
Scientists with the help of next gen Artificial Intelligence managed to create the smallest and most efficient camera in the world. A specialist medical camera that measures just under a nanometer has just entered the Guinness Book of Records. The size of the grain of sand, it is the camera’s tiny sensor that is actually being entered into the world-famous record book, for being the smallest commercially available image sensor.
–
TIMESTAMPS:
00:00 A new leap in Material Science.
00:57 How this new technology works.
03:45 Artificial Intelligence and Material Science.
06:00 The Privacy Concerns of Tiny Cameras.
07:45 Last Words.
–
#ai #camera #technology
Let me back up a moment. I recently concurred with megapundit Steven Pinker that over the last two centuries we have achieved material, moral and intellectual progress, which should give us hope that we can achieve still more. I expected, and have gotten, pushback. Pessimists argue that our progress will prove to be ephemeral; that we will inevitably succumb to our own nastiness and stupidity and destroy ourselves.
Maybe, maybe not. Just for the sake of argument, let’s say that within the next century or two we solve our biggest problems, including tyranny, injustice, poverty, pandemics, climate change and war. Let’s say we create a world in which we can do pretty much anything we choose. Many will pursue pleasure, finding ever more exciting ways to enjoy themselves. Others may seek spiritual enlightenment or devote themselves to artistic expression.
No matter what our descendants choose to do, some will surely keep investigating the universe and everything in it, including us. How long can the quest for knowledge continue? Not long, I argued 25 years ago this month in The End of Science, which contends that particle physics, cosmology, neuroscience and other fields are bumping into fundamental limits. I still think I’m right, but I could be wrong. Below I describe the views of three physicists—Freeman Dyson, Roger Penrose and David Deutsch—who hold that knowledge seeking can continue for a long, long time, and possibly forever, even in the face of the heat death of the universe.
Researchers at Microsoft have developed a faster way to write data into DNA — a biological alternative to the bits on a hard drive.
The development of therapies that are capable of safely achieving sizeable and sustained body weight loss has proved tremendously challenging. Here, Müller et al. provide an overview of the history of anti-obesity drug development, focusing on lessons learned, ongoing challenges and recent advances in the field.
